Gluten Intolerance Treatment Market Share

  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Gluten Intolerance Treatment Market Share

European Market Forecast

The Europe gluten intolerance treatment market is slated to register about 34% revenue share by the end of 2036. The increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance will drive its treatment market in the region.

The prevalence of celiac disease, primarily in Northern European, specifically, in countries like Finland that have a relatively high rate of this condition is gradually leading the region towards improved methods of diagnosis and recognition and treatment of such conditions, bolstering the regional market expansion. Nearly 2.5% of all adults between the ages of 30 and 64 have been diagnosed with celiac disease in Finland.

APAC Market Statistics

The Asia Pacific region is projected to account for 25% of the overall gluten intolerance treatment market share by 2036. The growing concern about gluten intolerance that is on the rise among Asians, especially among the population of China and India is anticipated to boost the market demand in the region.

China and India are the most populous countries in the world and the increasing evolution of modern farming practices for wheat cultivation, with advancements in food processing, has resulted in higher gluten content in wheat which is considered a major factor that will lead to the higher incidence of gluten intolerance in the region.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5081
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gluten intolerance treatment is estimated at USD 832.97 Million.

The gluten intolerance treatment market size was valued at USD 740.35 Million in 2023 and is likely to cross USD 4.02 Billion by the end of 2036, registering more than 13.9% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the market growth.

Asia Pacific region is projected to account for 25% revenue share by 2036, due to growing concern about gluten intolerance in the region.

Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample